Company intelligence / Profile preview

Vignette Bio

California, United States

Ownership: Private
Development stage: Other

Overview

Vignette Bio’s lead program was a BCMAxCD3 bispecific T-cell engager (previously EMB-06), licensed from EpimAb, which had demonstrated promising activity in patients with multiple myeloma; Vignette aimed to advance this and related assets into autoimmune and immunology indications. Clinical data on autoimmune indications is still in early stages[1][2][3].

Therapeutic areas: Immunology
Modalities: Bispecific monoclonal antibodyAntibody
Industry: Biotech

Partnerships

EpimAb Biotherapeutics (licensing of EMB-06/CND106)[1][3]

Beyond the preview

Go deeper on Vignette Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Vignette Bio.

Explore the full profile